ArticleiScience2026
Diagnostic value of combined serum CEA and CA19-9 in colorectal cancer A meta-analysis.
Article in iScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Colorectal cancer (CRC) is a leading cause of cancer-related mortality worldwide, and early detection remains critical for improving patient outcomes. Serum tumor markers carcino-embryonic antigen (CEA) and carbohydrate antigen 19-9 (CA19-9) are widely used in CRC diagnosis, yet their individual performance is limited. This meta-analysis systematically evaluated the diagnostic performance of CEA, CA19-9, and their combination across 95 studies (22,821 subjects). The combined CEA+CA19-9 testing achieved a pooled sensitivity of 0.585, specificity of 0.877, and diagnostic odds ratio of 9.99-representing improvements of 74% and 138% over CEA and CA19-9 alone, respectively. The area under the summary receiver operating characteristic (SROC) curve reached 0.783 for combined testing. Clinical utility analyses using Fagan's nomogram and likelihood ratio scatterplots confirmed the superiority of the multi-marker strategy. These findings provide evidence-based support for implementing combined tumor marker testing in clinical CRC diagnosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.